Ivarmacitinib with camrelizumab and apatinib for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (ivarmacitinib, camrelizumab, and apatinib) for people with advanced liver cancer that has stopped responding to initial immunotherapy. It aims to see if this triple therapy can help shrink or control the tumor when prior treatment has failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (BCLC stage B or C) that cannot be removed by surgery.
- Your cancer has progressed after at least 4 cycles of a first-line immunotherapy (such as Camrelizumab, Atezolizumab, or Sintilimab) combined with targeted therapy, and you had a partial response before progression.
- You have at least one measurable tumor (by CT or MRI).
- You are in good general health (ECOG performance status 0 or 1).
- Your liver, kidney, and blood function meet certain lab values (e.g., platelets at least 60, hemoglobin above 9, bilirubin not too high).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy, plus Apatinib, a targeted therapy) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial tests whether combining two drugs, camrelizumab (an immunotherapy) and apatinib (a targeted therapy), can prevent liver cancer from coming back in people who've had surgery or ablation to remove their tumor. It's for patients with a high risk of recurrence.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Hear when a new Resistance to Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.